HomeCompareAGOAF vs PFE

AGOAF vs PFE: Dividend Comparison 2026

AGOAF yields 2000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGOAF wins by $1.6247481716182984e+23M in total portfolio value
10 years
AGOAF
AGOAF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full AGOAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AGOAF vs PFE

📍 AGOAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGOAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGOAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGOAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGOAF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AGOAF beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGOAF + PFE for your $10,000?

AGOAF: 50%PFE: 50%
100% PFE50/50100% AGOAF
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AGOAF
No analyst data
Altman Z
-5.4
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGOAF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGOAFPFE
Forward yield2000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$1.6247481716182984e+23M$49.6K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$26,258.71
Total dividends collected$1.6146053563276882e+23M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AGOAF vs PFE ($10,000, DRIP)

YearAGOAF PortfolioAGOAF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$100,010,700$100,000,000.00$9,153$693.39+$100.00MAGOAF
2$467,446,731,075$467,339,719,626.17$8,593$849.25+$467446.72MAGOAF
3$1,021,215,363,816,662$1,020,715,195,814,411.90$8,336$1,066.78+$1021215363.81MAGOAF
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$8,437$1,384.80+$1043112617104.10MAGOAF
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$9,013$1,875.40+$498482143759731.38MAGOAF
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$10,306$2,680.72+$111599275650097776.00MAGOAF
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$12,820$4,101.38+$11738678336351557632.00MAGOAF
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$17,673$6,826.70+$583674362697175072768.00MAGOAF
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$27,543$12,591.86+$1.3894210989607547e+22MAGOAF
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$49,560$26,258.71+$1.6247481716182984e+23MAGOAF

AGOAF vs PFE: Complete Analysis 2026

AGOAFStock

Abengoa, S.A., together with its subsidiaries, provides technology solutions for the energy and water sectors in Spain and rest of Europe, North America, Brazil and rest of South America, Europe, Africa, and the Middle East. It operates through two segments, Engineering and Construction, and Concession-Type Infrastructures. The Engineering and Construction segment offers engineering services, including turnkey projects for thermo-solar plants, solar-gas hybrid plants, conventional generation plants, biofuels plants, and water infrastructures, as well as large-scale desalination plants and transmission lines, and others. It is also involved in the development of solar thermal and water management technologies; and technological business activities, such as hydrogen or the management of energy crops. The Concession-Type Infrastructure segment undertakes take-or-pay contracts or power purchase agreements comprising the operation of electric energy generation plants that include solar, cogeneration, or wind, as well as desalination plants and transmission lines. Abengoa, S.A. was founded in 1941 and is headquartered in Seville, Spain.

Full AGOAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AGOAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGOAF vs SCHDAGOAF vs JEPIAGOAF vs OAGOAF vs KOAGOAF vs MAINAGOAF vs JNJAGOAF vs MRKAGOAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.